Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice SA Scarneo, LS Eibschutz, PJ Bendele, KW Yang, J Totzke, P Hughes, ... Arthritis research & therapy 21, 1-10, 2019 | 42 | 2019 |
Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion SA Scarneo, A Mansourati, LS Eibschutz, J Totzke, JR Roques, D Loiselle, ... Scientific reports 8 (1), 17058, 2018 | 34 | 2018 |
TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases J Totzke, SA Scarneo, KW Yang, TAJ Haystead Open biology 10 (9), 200099, 2020 | 31 | 2020 |
A highly selective inhibitor of interleukin-1 receptor–associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase SA Scarneo, PF Hughes, KW Yang, DA Carlson, D Gurbani, KD Westover, ... Journal of Biological Chemistry 295 (6), 1565-1574, 2020 | 25 | 2020 |
Development and efficacy of an orally bioavailable selective TAK1 inhibitor for the treatment of inflammatory arthritis S Scarneo, P Hughes, R Freeze, K Yang, J Totzke, T Haystead ACS chemical biology 17 (3), 536-544, 2022 | 15 | 2022 |
TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades SA Scarneo, KW Yang, JR Roques, A Dai, LS Eibschutz, P Hughes, ... Oncotarget 11 (21), 1961, 2020 | 12 | 2020 |
Transforming growth factor-β-activated kinase 1 (TAK1) mediates chronic pain and cytokine production in mouse models of inflammatory, neuropathic, and primary pain S Scarneo, X Zhang, Y Wang, J Camacho-Domenech, J Ricano, ... The journal of pain 24 (9), 1633-1644, 2023 | 5 | 2023 |
Expression of membrane Hsp90 is a molecular signature of T cell activation SA Scarneo, AP Smith, J Favret, R O’Connell, J Pickeral, KW Yang, ... Scientific Reports 12 (1), 18091, 2022 | 5 | 2022 |
Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis S Bale, P Verma, B Yalavarthi, SA Scarneo, P Hughes, MA Amin, PS Tsou, ... JCI insight 8 (14), 2023 | 4 | 2023 |
Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis R Freeze, KW Yang, T Haystead, P Hughes, S Scarneo Pharmacology Research & Perspectives 11 (4), e01124, 2023 | 3 | 2023 |
Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain Y Wang, SA Scarneo, SH Kim, X Zhang, J Chen, KW Yang, P Hughes, ... Pain 163 (6), 1091-1101, 2022 | 3 | 2022 |
Investigation of SARS-CoV-2 individual proteins reveals the in vitro and in vivo immunogenicity of membrane protein T Haystead, E Lee, K Cho, G Gullickson, P Hughes, G Krafsur, R Freeze, ... Scientific Reports 13 (1), 22873, 2023 | 2 | 2023 |
Transforming Growth Factor-β-Activated Kinase 1 (TAK1) Alleviates Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis Preclinical Models R Freeze, P Hughes, T Haystead, S Scarneo Journal of Pain Research, 2287-2298, 2024 | | 2024 |
TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers H Damhofer, T Tatar, B Southgate, S Scarneo, K Agger, D Shlyueva, ... Cell Death & Disease 15 (4), 273, 2024 | | 2024 |
Compounds for Disease Treatment S Scarneo, PF Hughes, A Neely, TAJ Haystead US Patent App. 18/273,843, 2024 | | 2024 |
Chemotherapy-induced Peripheral Neuropathy: A Mini-review of Current & Developmental Treatments R Freeze, S Scarneo Journal of Neuroscience and Neurological Disorders 8 (1), 020-023, 2024 | | 2024 |
Targeting the TAK1/TNF signaling pathway with novel pharmacological inhibitors S Scarneo, T Haystead, P Hughes, R Freeze Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
Expression of membrane Hsp90 is a molecular signature of T cell activation JJKTAJH Scott A. Scarneo, Aaron P. Smith1,, Jacob Favret, Robert O’Connell ... Scientific Reports 12, 2022 | | 2022 |
599 Selective inhibition Of fibro-inflammatory kinase TAK1: A potential therapeutic strategy to ameliorate systemic sclerosis S Bale, P Verma, B Yalavarthi, SA Scarneo, TA Haystead, ... Journal of Investigative Dermatology 142 (8), S102, 2022 | | 2022 |
Pharmacological Inhibition of TAK1 as a Therapeutic Target to Reduce Inflammation and Pain SA Scarneo Duke University, 2020 | | 2020 |